Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Type 2 diabetes (T2D) is a public health threat. Prediabetes represents a window of opportunity for intervention to prevent T2D. Men with T2D and prediabetes often have low testosterone. Since testosterone improves glycemic control in T2D, we investigated whether testosterone therapy (TTh) in men with hypogonadism and prediabetes prevents progression to T2D. RESEARCH DESIGN AND METHODS: Three hundred and sixteen men with prediabetes (defined as HbA1c 5.7–6.4%) and total testosterone levels ≤12.1 nmol/L combined with symptoms of hypogonadism were analyzed. Two hundred and twenty-nine men received parenteral testosterone undecanoate (T-group), and 87 men with hypogonadism served as untreated control subjects. Metabolic and anthropometric parameters were measured twice yearly for 8 years. RESULTS: HbA1c decreased by 0.39 ± 0.03% (P < 0.0001) in the T-group and increased by 0.63 ± 0.1% (P < 0.0001) in the untreated group. In the T-group, 90% achieved normal glucose regulation (HbA1c <5.7%). In the untreated group, 40.2% progressed to T2D (HbA1c >6.5%). TTh was also associated with significant improvements in fasting glucose, triglyceride:HDL ratio, triglyceride-glucose index, lipid accumulation product, total cholesterol, LDL, HDL, non-HDL, triglycerides, and Aging Males’ Symptoms (AMS) scale. Significant deterioration in all these parameters was seen in the untreated group. Mortality was 7.4% in the T-group and 16.1% in the untreated group (P < 0.05). The incidence of nonfatal myocardial infarction was 0.4% in the T-group and 5.7% in the untreated group (P < 0.005). CONCLUSIONS: Long-term TTh completely prevents prediabetes progression to T2D in men with hypogonadism and improves glycemia, lipids, and AMS score. TTh holds tremendous potential for the large and growing population of men with prediabetes and hypogonadism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There appears to be a higher likelihood for undiagnosed hyperglycemia in those seeking fertility.1557”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1557]
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Guerrero-Romero, F., Simental-Mendía, L. E., González-Ortiz, M., Martínez-Abundis, E., Ramos-Zavala, M. G., Hernández-González, S. O., Jacques-Camarena, O., & Rodríguez-Morán, M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0288 · Cited by 2,247
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 2×
“above which further weight loss may not result in additional preventive benefits (11).”
BackgroundSelf-citationSex differences in metabolic regulation and diabetes susceptibility
Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J.-F., Montagner, A., & Gourdy, P. (2020) · Diabetologia · doi:10.1007/s00125-019-05040-3 · Cited by 923
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865 · cited 2×
“Clinical trials assessing efficacy of lifestyle interventions as well as pharmacotherapy for obesity are characterized by high attrition rates (22).”
BackgroundEight-year weight losses with an intensive lifestyle intervention: The look AHEAD study
The Look AHEAD Research Group (2014) · Obesity · doi:10.1002/oby.20662 · Cited by 842
The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study
Bommer, C., Heesemann, E., Sagalova, V., Manne-Goehler, J., Atun, R., Bärnighausen, T., & Vollmer, S. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30097-9 · Cited by 816 · cited 1×
“In 2017, therewere 451million people (ages 18–99 years) with diabetes worldwide, and 5million deaths were attributable to diabetes (39).”
BackgroundKapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791 · cited 1×
“is likely improvement in insulin sensitivity (29,30).”
Srikanthan, P., & Karlamangla, A. S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0435 · Cited by 785
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
The TyG index may predict the development of cardiovascular events
Sánchez‐Íñigo, L., Navarro‐González, D., Fernández‐Montero, A., Pastrana‐Delgado, J., & Martínez, J. A. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12583 · Cited by 663
McLaughlin, T., Reaven, G., Abbasi, F., Lamendola, C., Saad, M., Waters, D., Simon, J., & Krauss, R. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.03.085 · Cited by 658 · cited 2×
“5 provides a simplemeansof identifying patientswith IR and dyslipidemia (17).”
BackgroundFrequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0804 · Cited by 631 · cited 1×
“glycemic control, duration of disease, and obesity, was published in 2004 (4).”
BackgroundJones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Morales, A. M., Volterrani, M., Yellowlees, A., Howell, J. D., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1233 · Cited by 548
Muraleedharan, V., Marsh, H., Kapoor, D., Channer, K. S., & Jones, T. H. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0321 · Cited by 389
Testosterone concentrations in diabetic and nondiabetic obese men
Dhindsa, S., Miller, M. G., McWhirter, C. L., Mager, D. E., Ghanim, H., Chaudhuri, A., & Dandona, P. (2010) · Diabetes Care · doi:10.2337/dc09-1649 · Cited by 352 · cited 1×
“In a later study, the prevalence of hypogonadism in lean, overweight, and obese men with T2D was significantly higher than in men without T2D (5).”
ResultGrundy, S. M. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 347
Grundy, S. M., Arai, H., Barter, P., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A., Davidson, M. H., Genest, J., Kesäniemi, Y. A., et al. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 327
Dhindsa, S., Ghanim, H., Batra, M., Kuhadiya, N. D., Abuaysheh, S., Sandhu, S., Green, K., Makdissi, A., Hejna, J., Chaudhuri, A., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1518 · Cited by 286 · cited 1×
“receptor, and the insulin receptor substrate 1, providing an enhanced capacity for insulin-mediated glucose transport (31).”
BackgroundLigthart, S., van Herpt, T. T. W., Leening, M. J. G., Kavousi, M., Hofman, A., Stricker, B. H. C., van Hoek, M., Sijbrands, E. J. G., Franco, O. H., & Dehghan, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00362-9 · Cited by 267 · cited 1×
“Several studies have reported that men with impaired fasting glucose or impaired glucose tolerance have biochemical evidence of hypogonadism compared with euglycemic peers (3,8,9).”
BackgroundLiu, J., Sempos, C., Donahue, R. P., Dorn, J., Trevisan, M., & Grundy, S. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1916 · Cited by 239 · cited 1×
“disease death than LDL in people with diabetes (34).”
BackgroundVega, G. L., Barlow, C. E., Grundy, S. M., Leonard, D., & DeFina, L. F. (2014) · Journal of Investigative Medicine · doi:10.2310/jim.0000000000000044 · Cited by 235
Corona, G., Giagulli, V. A., Maseroli, E., Vignozzi, L., Aversa, A., Zitzmann, M., Saad, F., Mannucci, E., & Maggi, M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0262 · Cited by 217 · cited 2×
“Another contributing factor to the prevention of prediabetes progression to diabetes is the consistent increase in lean body mass with TTh (26).”
BackgroundSelf-citationGoodman-Gruen, D., & Barrett-Connor, E. (2000) · Diabetes Care · doi:10.2337/diacare.23.7.912 · Cited by 203
Prediabetes and associated disorders
Buysschaert, M., Medina, J. L., Bergman, M., Shah, A., & Lonier, J. (2014) · Endocrine · doi:10.1007/s12020-014-0436-2 · Cited by 183 · cited 1×
“and type 2 diabetes mellitus (T2D) (1,2).”
Grams, J. M., & Garvey, W. T. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0155-x · Cited by 145 · cited 3×
“the prevention of prediabetes progression to diabetes (10).”
BackgroundInfluentialSelf-citationSaad, F., Yassin, A., Doros, G., & Haider, A. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.139 · Cited by 131 · cited 2×
“(13), we hypothesized that men with hypogonadism and prediabetes, defined as glycated hemoglobin (HbA1c) 5.”
BackgroundMethodSelf-citationTraish, A. M., Haider, A., Haider, K. S., Doros, G., & Saad, F. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417691136 · Cited by 130 · cited 3×
“cardial infarction demonstrated in our study and to the reduction in cardiovascular mortality that has been reported previously inastudyof long-termTTh(14).”
MethodResultSelf-citationNational lipid association annual summary of clinical lipidology 2016
Bays, H. E., Jones, P. H., Orringer, C. E., Brown, W. V., & Jacobson, T. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.002 · Cited by 128 · cited 2×
“Society (35), and the National Lipid Association (36), stress the importance of nonHDL and recommend that non-HDL replaces LDL as the primary therapeutic target for reducing CVD risk in patients with diabetes.”
BackgroundHulmán, Á., Simmons, R. K., Brunner, E. J., Witte, D. R., Færch, K., Vistisen, D., Ikehara, S., Kivimäki, M., & Tabák, Á. G. (2017) · Diabetologia · doi:10.1007/s00125-017-4275-6 · Cited by 113 · cited 1×
“theonsetof thediabetogenicprocess starts 10–20 years before the diagnosis of overt T2D (37,38).”
BackgroundAssociation of Endogenous Sex Hormones With Diabetes andImpaired Fasting Glucose in Men
Colangelo, L. A., Ouyang, P., Liu, K., Kopp, P., Golden, S. H., Dobs, A. S., Szklo, M., Vaidya, D., Cushman, M., & Gapstur, S. M. (2009) · Diabetes Care · doi:10.2337/dc08-2216 · Cited by 90
Kalyani, R. R., Metter, E. J., Ramachandran, R., Chia, C. W., Saudek, C. D., & Ferrucci, L. (2012) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glr022 · Cited by 86 · cited 3×
“Accordingly, several studies showed that a larger muscle mass is associated with higher insulin sensitivity, lower HbA1c, and reduced risk for prediabetes and overt T2D inbotholderandyoungerpeople (27,28).”
BackgroundInfluentialGyawali, P., Martin, S., Heilbronn, L. K., Vincent, A. D., Taylor, A. W., Adams, R., O’Loughlin, P. D., & Wittert, G. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1163-6 · Cited by 63 · cited 1×
“and type 2 diabetes mellitus (T2D) (1,2).”
The challenge of a 2-year follow-up after intervention for weight loss in primary care
Holzapfel, C., Cresswell, L., Ahern, A. L., Fuller, N. R., Eberhard, M., Stoll, J., Mander, A. P., Jebb, S. A., Caterson, I. D., & Hauner, H. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.180 · Cited by 51
Giagulli, V. A., Castellana, M., Murro, I., Pelusi, C., Guastamacchia, E., Triggiani, V., & Pergola, G. D. (2019) · Nutrients · doi:10.3390/nu11122975 · Cited by 45
Summary of Revisions: Standards of Medical Care in Diabetes—2018
(2017) · Diabetes Care · doi:10.2337/dc18-srev01 · Cited by 45
Hackett, G., Cole, N., Mulay, A., Strange, R. C., & Ramachandran, S. (2019) · BJU International · doi:10.1111/bju.14536 · Cited by 43
Wittert, G., Atlantis, E., Allan, C., Bracken, K., Conway, A., Daniel, M., Gebski, V., Grossmann, M., Hague, W., Handelsman, D. J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13601 · Cited by 37 · cited 1×
“A notable randomized placebo-controlled study is currently under way, the Testosterone for Diabetes Mellitus (T4DM) trial, that is investigating whether TTh combined with lifestyle change can prevent T2D in men who have low testosterone levels and prediabetes (40).”
BackgroundMalmström, H., Walldius, G., Carlsson, S., Grill, V., Jungner, I., Guðbjörnsdóttir, S., Kosiborod, M., & Hammar, N. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13241 · Cited by 35 · cited 1×
“theonsetof thediabetogenicprocess starts 10–20 years before the diagnosis of overt T2D (37,38).”
BackgroundMark, L., Vallejo-Vaz, A. J., Reiber, I., Paragh, G., Kondapally Seshasai, S. R., & Ray, K. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.810 · Cited by 30 · cited 1×
“Non-HDL represents the cholesterol content of all proatherogenic, apo-B– containing lipoproteins (15) and is calculated as total cholesterol minus HDL.”
BackgroundThe Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
Kırlangıç, O. F., Yilmaz‐Oral, D., Kaya‐Sezginer, E., Toktanis, G., Tezgelen, A. S., Sen, E., Khanam, A., Öztekin, Ç. V., & Gür, S. (2020) · Sexual Medicine · doi:10.1016/j.esxm.2020.02.006 · Cited by 23
The prevalence of prediabetes in population of polish men with late-onset hypogonadism
Rabijewski, M., Papierska, L., & Piątkiewicz, P. (2014) · The Aging Male · doi:10.3109/13685538.2014.936000 · Cited by 19
Sinha, D. K., Balasubramanian, A., Tatem, A. J., Mirabal, J. L. R., Yu, J., Kovac, J. R., Pastuszak, A. W., & Lipshultz, L. I. (2020) · Translational Andrology and Urology · doi:10.21037/tau.2019.11.30 · Cited by 13
Change in nonhigh-density lipoprotein cholesterol levels in adults with prediabetes
Liu, J.-R., Liu, B., & Yin, F. (2017) · Medicine · doi:10.1097/md.0000000000008461 · Cited by 10
Testosterone Replacement Therapy and the Risk of Hypoglycemia
Yamaguchi, A. V., Costanzo, P., Peuchot, V. A., & Knoblovits, P. (2019) · Case Reports in Endocrinology · doi:10.1155/2019/9616125 · Cited by 7
Research works printed but not linked: 1
- Saad, 2017, Most hypogonadal men with type 2 diabetes mellitus (T2DM) achieve HbA1c targets when treated with testosterone undecanoate injections (TU) for up to 12 years, Diabetes, 66, A305
Cited by
Sex and gender: modifiers of health, disease, and medicine
Mauvais-Jarvis, F., Bairey Merz, N., Barnes, P. J., Brinton, R. D., Carrero, J.-J., DeMeo, D. L., De Vries, G. J., Epperson, C. N., Govindan, R., Klein, S. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31561-0 · Cited by 2,001
Sex differences in metabolic regulation and diabetes susceptibility
Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J.-F., Montagner, A., & Gourdy, P. (2020) · Diabetologia · doi:10.1007/s00125-019-05040-3 · Cited by 923
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationCorona, G., Goulis, D. G., Huhtaniemi, I., Zitzmann, M., Toppari, J., Forti, G., Vanderschueren, D., & Wu, F. C. (2020) · Andrology · doi:10.1111/andr.12770 · Cited by 431
Wittert, G., Bracken, K., Robledo, K. P., Grossmann, M., Yeap, B. B., Handelsman, D. J., Stuckey, B., Conway, A., Inder, W., McLachlan, R., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30367-3 · Cited by 362
Metadata
- Authors
- Yassin, A., Haider, A., Haider, K. S., Caliber, M., Doros, G., Saad, F., & Garvey, W. T.
- Affiliations
- Dresden International University (DE)
- Private Urology Practice, Bremerhaven, Germany
- American Medical Writers Association (US)
- Boston University (US)
- Gulf Medical University (AE)
- University of Alabama at Birmingham (US)
- Corresponding author
- Saad, Farid
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-03-12
- Volume
- 42
- Issue
- 6
- Pages
- 1104-1111
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2922405541
- Cited by
- 164
- References
- 45
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 20 · 2023: 26 · 2022: 31 · 2021: 26 · 2020: 26 · 2019: 11
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bayer AG
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- testosterone replacement therapy, hypogonadism, prediabetes, type 2 diabetes prevention, testosterone undecanoate, glycemic control, HbA1c, lipid profile, aging male symptoms, myocardial infarction, mortality, men
- MeSH terms
- Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Hypogonadism, Male, Middle Aged, Prediabetic State, Registries, Testosterone, Triglycerides, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.